{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_9233106_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"119-349-637-852-460","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8909,"type":"PATENT","title":"Cornell Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":11969,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8223,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
Search applicants and owners= \"Cornell Univ\", \" Univ Cornell\", \" Cornell Res* Found*\", \"Corne* Univ* Tech* Enter* Comm*\".
Select more for logical variant
Add to collection
Select all the results in the collect and expand by simple families
Add to collection
Total patent: 10677
administering to the subject a compound having the following structure:\n\nwherein\n
R1 is H, —COOCH3, or —COO−Li+; R2 is carbonyl, —COOH, or —COOCH3; R3 is H, —OH, -Ph, or -PhCl; and R4 is H or —S(O)2Ph, wherein if R2 is —COOCH3 then R3 is not H, conditions effective to treat or prevent Alzheimer's Disease in the subject."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein said compound comprises a cocaine analogue selected from the group consisting of ecgonine, ecgonine methyl ester, RTI-4229-70, RCS-III-143, RCS-III-140A, RCS-III-218, and RCS-III-202A."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein said administering is carried out orally, parenterally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, transdermally, or by application to mucous membranes."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the compound is administered with a pharmaceutically acceptable carrier."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 1, wherein the subject is a human."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A method of inhibiting aggregation of beta-amyloid peptides in a subject, said method comprising:\n
selecting a subject having an increased aggregation of beta-amyloid peptides as compared to a healthy subject and\n
administering to the selected subject a compound having the following structure:\n\nwherein\n
R1 is H, —COOCH3, or —COO−Li+; R2 is carbonyl, —COOH, or —COOCH3; R3 is H, —OH, -Ph, or -PhCl; and R4 is H or —S(O)2Ph, wherein if R2 is —COOCH3 then R3 is not H, under conditions effective to inhibit aggregation of beta-amyloid peptides in the subject."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said compound comprises a cocaine analogue selected from the group consisting of ecgonine, ecgonine methyl ester, RTI-4229-70, RCS-III-143, RCS-III-140A, RCS-III-218, and RCS-III-202A."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said beta-amyloid peptide is selected from the group consisting of beta-amyloid peptide Aβ(1-40) and beta-amyloid peptide Aβ(1-42)."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein said administering is carried out orally, parenterally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, transdermally, or by application to mucous membranes."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein the compound is administered with a pharmaceutically acceptable carrier."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 6, wherein the subject is a human."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}